Folic acid-mediated re-shuttling of ferritin receptor specificity towards a selective delivery of highly cytotoxic nickel(II) coordination compounds

Tesařová, Barbora; Charousova, Marketa; Dostálová, Simona; Bieńko, Alina; Kopel, Pavel; Kruszyński, Rafał; Hynek, David; Michálek, Petr; Eckschlager, Tomáš; Stiborová, Marie; Adam, Vojtěch; Heger, Zbyněk

doi:10.1016/j.ijbiomac.2018.12.128

Cited by 20 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the oxidation peaks at the same potentials as ttc can be observed in the CV of complex 2, indicating the existence of ttc in the complex. It is very probable that benzimidazole rings do not influence the electrochemical behavior of the complex due to the conformation of tebb ligands showing facial-like coordination with two nitrogen atoms of benzimidazoles in plane of octahedron and sulfur atom of benzimidazole in apical position causing twist of benzimidazole rings as reported before [28]. It is also possible that aliphatic chains in ligands do not allow for a simple exchange of electrons.…”

Section: Electrochemical Studymentioning

confidence: 84%

“…, and [Ni 3 (pmdien) 3 (µ-ttc)] (ClO 4 ) 3 (3), were previously reported [26][27][28] (Scheme 1). Here, we report on the electrochemical behavior of complexes that have not been studied yet.…”

Section: Introductionmentioning

confidence: 94%

“…Perchlorate anions and hydrogen atoms were omitted for clarity. The structural data of the complexes can be found in [26][27][28]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

An Investigation on the Electrochemical Behavior and Antibacterial and Cytotoxic Activity of Nickel Trithiocyanurate Complexes

2020

Self Cite

View full text Add to dashboard Cite

The electrochemical redox behavior of three trinuclear Ni(II) complexes [Ni3(abb)3(H2O)3(µ-ttc)](ClO4)3 (1), [Ni3(tebb)3(H2O)3(µ-ttc)](ClO4)3·H2O (2), and [Ni3(pmdien)3(µ-ttc)](ClO4)3 (3), where abb = 1-(1H-benzimidazol-2-yl)-N-(1H-benzimidazol-2-ylmethyl)methan-amine, ttcH3 = trithiocyanuric acid, tebb = 2-[2-[2-(1H-benzimidazol-2-yl)ethylsulfanyl]ethyl]-1H-benzimidazole, and pmdien = N,N,N′,N″,N″-pentamethyldiethylenetriamine is reported. Cyclic voltammetry (CV) was applied for the study of the electrochemical behavior of these compounds. The results confirmed the presence of ttc and nickel in oxidation state +2 in the synthesized complexes. Moreover, the antibacterial properties and cytotoxic activity of complex 3 was investigated. All the complexes show antibacterial activity against Staphylococcus aureus and Escherichia coli to different extents. The cytotoxic activity of complex 3 and ttcNa3 were studied on G-361, HOS, K-562, and MCF7 cancer cell lines. It was found out that complex 3 possesses the cytotoxic activity against the tested cell lines, whereas ttcNa3 did not show any cytotoxic activity.

show abstract

Section: Electrochemical Studymentioning

confidence: 84%

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

An Investigation on the Electrochemical Behavior and Antibacterial and Cytotoxic Activity of Nickel Trithiocyanurate Complexes

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…For this purpose, mouse anti-hNET antibody (MAB5620, Merck Millipore, Burlington, MA, USA, 1:500) and anti-mouse antibody labeled with Cruz Fluor ™ 647 (sc362287, Santa Cruz Biotechnology, 1:500) were used. The protocol was adapted from our previous work [52].…”

Section: Expression Of L-frt Surface Receptor Scara5 and Hnetmentioning

confidence: 99%

“…To mimic other in vivo conditions, 37 °C and 600 rpm was employed for 35 min. The hard protein coronas were recovered and visualized as described in Tesarova et al [52]. Hemotoxicity for red blood cells, as well as genotoxicity (single-cell gel electrophoresis) for off-target cells (HBL-100) were checked also according Tesarova et al [52].…”

Section: Nanovehicle Biocompatibilitymentioning

confidence: 99%

Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Currently, the diagnosis and treatment of neuroblastomas-the most frequent solid tumors in children-exploit the norepinephrine transporter (hNET) via radiolabeled norepinephrine analogs. We aim to develop a nanomedicine-based strategy towards precision therapy by targeting hNET cell-surface protein with hNET-derived homing peptides. Results: The peptides (seq. GASNGINAYL and SLWERLAYGI) were shown to bind high-resolution homology models of hNET in silico. In particular, one unique binding site has marked the sequence and structural similarities of both peptides, while most of the contribution to the interaction was attributed to the electrostatic energy of Asn and Arg (< − 228 kJ/mol). The peptides were comprehensively characterized by computational and spectroscopic methods showing ~ 21% β-sheets/aggregation for GASNGINAYL and ~ 27% α-helix for SLWERLAYGI. After decorating 12-nm ferritin-based nanovehicles with cysteinated peptides, both peptides exhibited high potential for use in actively targeted neuroblastoma nanotherapy with exceptional in vitro biocompatibility and stability, showing minor yet distinct influences of the peptides on the global expression profiles. Upon binding to hNET with fast binding kinetics, GASNGINAYLC peptides enabled rapid endocytosis of ferritins into neuroblastoma cells, leading to apoptosis due to increased selective cytotoxicity of transported payload ellipticine. Peptide-coated nanovehicles significantly showed higher levels of early apoptosis after 6 h than non-coated nanovehicles (11% and 7.3%, respectively). Furthermore, targeting with the GASNGINAYLC peptide led to significantly higher degree of late apoptosis compared to the SLW-ERLAYGIC peptide (9.3% and 4.4%, respectively). These findings were supported by increased formation of reactive oxygen species, down-regulation of survivin and Bcl-2 and up-regulated p53. Conclusion: This novel homing nanovehicle employing GASNGINAYLC peptide was shown to induce rapid endocytosis of ellipticine-loaded ferritins into neuroblastoma cells in selective fashion and with successful payload. Future homing peptide development via lead optimization and functional analysis can pave the way towards efficient peptide-based active delivery of nanomedicines to neuroblastoma cells.

show abstract

Conventional Nanosized Drug Delivery Systems for Cancer Applications

Vergallo

Hafeez

Iannotta

et al. 2021

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Clinical responses and tolerability of conventional nanocarriers (NCs) are sometimes different from those expected in anticancer therapy. Thus, new smart drug delivery systems (DDSs) with stimuli-responsive properties and novel materials have been developed. Several clinical trials demonstrated that these DDSs have better clinical therapeutic efficacy in the treatment of many cancers than free drugs. Composition of DDSs and their surface properties increase the specific targeting of therapeutics versus cancer cells, without affecting healthy tissues, and thus limiting their toxicity versus unspecific tissues. Herein, an extensive revision of literature on NCs used as DDSs for cancer applications has been performed using the available bibliographic databases.

show abstract

Folic acid-mediated re-shuttling of ferritin receptor specificity towards a selective delivery of highly cytotoxic nickel(II) coordination compounds

Cited by 20 publications

References 36 publications

An Investigation on the Electrochemical Behavior and Antibacterial and Cytotoxic Activity of Nickel Trithiocyanurate Complexes

An Investigation on the Electrochemical Behavior and Antibacterial and Cytotoxic Activity of Nickel Trithiocyanurate Complexes

Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells

Conventional Nanosized Drug Delivery Systems for Cancer Applications

Contact Info

Product

Resources

About